Compare SSTK & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | SCTX |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.9M | 536.5M |
| IPO Year | 2012 | 2026 |
| Metric | SSTK | SCTX |
|---|---|---|
| Price | $4.19 | $15.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | ★ 623.8K | 428.1K |
| Earning Date | 11-05-2026 | 11-29-2026 |
| Dividend Yield | ★ 24.19% | N/A |
| EPS Growth | ★ 23.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $13.50 |
| 52 Week High | $23.82 | $39.60 |
| Indicator | SSTK | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 35.82 |
| Support Level | $3.76 | $13.50 |
| Resistance Level | $4.74 | $22.07 |
| Average True Range (ATR) | 0.24 | 2.19 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 27.92 | 4.02 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.